Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE‐IT Investigators. Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention: insights from REDUCE-IT PCI. J Am Heart Assoc. 2022; epub ahead of print.

https://www.ahajournals.org/doi/epub/10.1161/JAHA.121.022937

https://pubmed.ncbi.nlm.nih.gov/35261279/

Chapman MJ, Zamorano JL, Parhofer KG. Reducing residual cardiovascular risk in Europe: therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Pharmacol Ther. 2022 Mar 15; epub ahead of print.

https://www.sciencedirect.com/science/article/abs/pii/S0163725822000663

https://doi.org/10.1016/j.pharmthera.2022.108172

Singh N, Bhatt DL, Miller M, Steg G, Brinton EA, Jacobson TA, Jiao L, Tardif J-C, Mason RP, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Consistency of benefit of icosapent ethyl by background statin type in REDUCE-IT. J Am Coll Cardiol. 2022;79:220-222.

https://www.jacc.org/doi/10.1016/j.jacc.2021.11.005

Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, King JB, Bellows BK, Tajeu GS, Derington CG, Johnson J, Andrade K, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P. Cost-effectiveness of icosapent ethyl for high-risk patients with hypertriglyceridemia despite statin treatment. JAMA Netw Open. 2022;5(2):e2148172.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789004

https://pubmed.ncbi.nlm.nih.gov/35157055/

Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE-IT Investigators. Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT REVASC. Circulation. 2021;143:33-44.

https://pubmed.ncbi.nlm.nih.gov/33148016/

Picard F, Bhatt DL, Ducrocq G, Ohman EM, Goto S, Eagle KA, Wilson PWF, Smith SC, Elbez Y, Steg PG. Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: an analysis of the REduction of Atherothrombosis for Continued Health (REACH) Registry. Int J Cardiol. 2021;340:96-104.

https://www.internationaljournalofcardiology.com/article/S0167-5273(21)01297-3/fulltext

Boden WE, Baum S, Toth PP, Fazio S, Bhatt DL. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Future Cardiol. 2021;17(1):155-174.

https://www.futuremedicine.com/doi/pdf/10.2217/fca-2020-0106

https://pubmed.ncbi.nlm.nih.gov/32959713/

Verma S, Bhatt DL, Steg G, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif J-C, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: REDUCE-IT CABG. Circulation. 2021;144:1845-1855.

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056290

https://pubmed.ncbi.nlm.nih.gov/34710343/

Olshansky B, Chung MK, Budoff MJ, Philip S, Jiao L, Doyle RT Jr, Copland C, Giaquinto A, Juliano RA, Bhatt DL. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J. 2020;22(Supplement J):J34-J48.

https://doi.org/10.1093/eurheartj/suaa117

Majithia A, Bhatt DL, Friedman AN, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Budoff M, Mason RP, Tardif JC, Boden WE, Ballantyne CM; REDUCE-IT Investigators. Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL. Circulation. 2021;144:1750-1759.

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055560

https://pubmed.ncbi.nlm.nih.gov/34706555/

Wang X, Verma S, Mason RP, Bhatt DL. The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction. Curr Diabetes Rep. 2020;20:65. https://link.springer.com/content/pdf/10.1007/s11892-020-01343-7.pdf

Radenkovic D, Olshansky B, Bhatt D. New insights into icosapent ethyl for patients with residual cardiovascular risk. EMJ Cardiol. 2020;8:34-40. https://www.emjreviews.com/cardiology/symposium/new-insights-into-icosapent-ethyl-for-patients-with-residual-cardiovascular-risk/

Bhatt DL. Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside. Eur Heart J. 2020;22(Supplement J):J1-J2. https://doi.org/10.1093/eurheartj/suaa114

O’Connell TD, Mason RP, Budoff MJ, Navar AM, Shearer GC. Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites. Eur Heart J. 2020;22(Supplement J):J3-J20. https://doi.org/10.1093/eurheartj/suaa115

Parhofer KG, Chapman MJ, Nordestgaard BG. Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap. Eur Heart J. 2020;22(Supplement J):J21-J33. https://doi.org/10.1093/eurheartj/suaa116

Olshansky B, Chung MK, Budoff MJ, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J. 2020;22(Supplement J):J34-J48. https://doi.org/10.1093/eurheartj/suaa117

Ferrari R, Censi S, Cimaglia P. The journey of omega-3 fatty acids in cardiovascular medicine. Eur Heart J. 2020;22(Supplement J):J49-J53. https://doi.org/10.1093/eurheartj/suaa118

Bhatt DL, Hull MA, Song M, Van Hulle C, Carlsson C, Chapman MJ, Toth PP. Beyond cardiovascular medicine: potential future uses of icosapent ethyl. Eur Heart J. 2020;22(Supplement J):J54-J64. https://doi.org/10.1093/eurheartj/suaa119

Boden WE, Baum S, Toth PP, et al. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Future Cardiol. 2020; epub ahead of print. https://www.futuremedicine.com/doi/pdf/10.2217/fca-2020-0106

Toth PP, Shah PK, Lepor NE. Targeting hypertriglyceridemia to mitigate cardiovascular risk: a review. Am J Prevent Cardiol. 2020; epub ahead of print. https://www.sciencedirect.com/science/article/pii/S2666667720300866

Olshansky B, Bhatt DL, Miller M, et al. on behalf of the REDUCE-IT Investigators. REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. Eur Heart J Cardiovasc Pharmacother. 2020; epub ahead of print. https://academic.oup.com/ehjcvp/advance-article/doi/10.1093/ehjcvp/pvaa118/5917630

Fan W, Philip S, Toth PP, et al. Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: results from National Health and Nutrition Examination Survey (NHANES) 2007-2014. Am J Prevent Cardiol. 2020; epub ahead of print. https://www.sciencedirect.com/science/article/pii/S2666667720300878

Wong ND, Fan W, Philip S, et al. REDUCE-IT eligibility and preventable cardiovascular events in the US population (from the National Health and Nutrition Examination Survey [NHANES]). Am J Cardiol. 2020; epub ahead of print.

https://www.ajconline.org/article/S0002-9149(20)30861-4/fulltext

Trivedi K, Le V, Nelson JR. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. Postgrad Med. 2020; epub ahead of print.

https://www.tandfonline.com/doi/full/10.1080/00325481.2020.1783937

Ferrières J, Bataille V, Puymirat E, Schiele F, Simon T, Danchin N, for the FAST-MI investigators. Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice? Clin Cardiol. 2020;1-6.

https://doi.org/10.1002/clc.23437